礼来在其革命性GLP-1糖尿病和肥胖症药物Mounjaro和Zepbound的推动下跃升至超大型公司行列，这些药物代表了数十年来最大的制药机遇之一。
礼来是一只占据主导地位的制药股票，受益于其GLP-1疗法Mounjaro和Zepbound的前所未有的商业成功，这些产品已将该公司推向肥胖症治疗革命的最前沿，并使其成为历史上估值最高的制药公司之一。
礼来凭借其GLP-1减肥和糖尿病药物Mounjaro和Zepbound成为世界上最有价值的公司之一，领导肥胖症治疗革命。
Data updated Feb 15 · Source: Twelve Data
Eli Lilly has emerged as one of the most compelling stories in pharma, driven primarily by its blockbuster GLP-1 receptor agonist tirzepatide (Mounjaro/Zepbound) for diabetes and weight loss. The stock's 415% five-year return reflects extraordinary investor enthusiasm for its pipeline and commercial execution.
The bull case is powerful: Lilly dominates the rapidly expanding weight management market alongside Novo Nordisk, with a potentially superior efficacy profile. Its broader pipeline spanning Alzheimer's (donanemab), immunology, and oncology provides diversification beyond GLP-1s. Revenue growth has been exceptional as manufacturing scales.
However, the valuation demands scrutiny. A P/E of 54.7x prices in years of flawless execution. Key risks include potential GLP-1 competition from oral alternatives, pricing pressure from government negotiations, and manufacturing capacity constraints. The stock trading ~8% below its 52-week high suggests some investor caution has crept in.
EPS of $19.00 TTM reflects strong profitability, but investors must weigh whether the premium valuation adequately accounts for execution risk. For long-term investors with conviction in the obesity treatment megatrend, Lilly remains best-in-class, though entry timing matters at these levels.
Eli Lilly has established itself as the premier growth story in the pharmaceutical sector, driven primarily by the unprecedented demand for its GLP-1 agonists, Mounjaro and Zepbound. Trading near $1,025, the stock commands a premium valuation with a P/E ratio of roughly 54, significantly higher than industry peers. However, this multiple reflects the massive earnings potential of its obesity and diabetes portfolio, alongside a promising pipeline that includes treatments for Alzheimer's disease. While the company faces challenges regarding manufacturing capacity to meet soaring demand and stiff competition from Novo Nordisk, its financial health remains robust with a TTM EPS of $19.00. For investors, LLY represents a high-conviction growth play, though the current price point requires confidence that the company can flawlessly execute its production ramp-up and maintain pricing power.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
每个交易员都有一个在脑子里看起来很好的策略。回测是您发现它是否实际有效的方式。以下是如何正确测试策略、哪些指标重要，以及为什么大多数回测结果好得不真实。
Powered by Rexiew